BiotechTube

KHK4827 + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate to Severe Systemic Sclerosis

Conditions

Moderate to Severe Systemic Sclerosis

Trial Timeline

May 23, 2019 → Apr 11, 2025

NCT ID
NCT03957681

About KHK4827 + Placebo

KHK4827 + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Moderate to Severe Systemic Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03957681. Target conditions include Moderate to Severe Systemic Sclerosis.

What happened to similar drugs?

7 of 20 similar drugs in Moderate to Severe Systemic Sclerosis were approved

Approved (7) Terminated (2) Active (12)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
🔄CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
🔄CT-P17 + EU-approved HumiraCelltrionPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄CS-3150Daiichi SankyoPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT04061252Phase 3Completed
NCT03957681Phase 3Completed
NCT02982005Phase 3Completed
NCT01748539Phase 2Completed

Competing Products

20 competing products in Moderate to Severe Systemic Sclerosis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
PexidartinibDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
Ranirestat + PlaceboEisaiPhase 2/3
38
E6007 + PlaceboEisaiPhase 2
35
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
35
KHK4827 + PlaceboKyowa KirinPhase 2
35
Stelara + Bmab1200BioconPhase 3
40
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringeBioconPhase 3
40